CD37

CD37

CD37 Overview

Molecule Name
Leukocyte antigen CD37
Synonyms
CD37,Tspan-26,TSPAN26
Drug Development Progress
Drugs in Clinical Trials9
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
CD37,Tetraspanin-26,CD37 Molecule,CD37 Antigen,Tspan-26,TSPAN26,Cell Differentiation Antigen 37,Leukocyte Surface Antigen CD37,Leukocyte Antigen CD37,GP52-40
Background
Leukocyte antigen CD37 (CD37) is also known as Tetraspanin-26 (Tspan-26) and TSPAN26,which is a member of the transmembrane 4 superfamily or tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins encoded by CD37 gene mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. CD37 may play a role in T-cell-B-cell interactions.

CD37 Product List

Species
  • Human(5)
Tag
  • -(2)
  • Fc Tag(2)
  • His Tag(1)
Host
  • HEK293(5)
Conjugate
  • Unconjugated(4)
  • FITC Labeled(1)
Grade
  • RUO(5)
Low Endotoxin
  • Yes(1)
  • No(4)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
CD37
Human CD37 Full Length Protein (VLP)
Human
HEK293
HPLC
ELISAIdentity

$620.00

20ug
CD37
Human CD37 Full Length Protein, His,Flag Tag (Detergent)
Human
HEK293
ELISASPR

$805.00

20ug
CD37
Human CD37 Protein, His Tag, low endotoxin
Human
HEK293
SDS-PAGE

$395.00

100ug
CD37
Human CD37 Protein, Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE

$360.00

100ug
CD37
FITC-Labeled Human CD37 Protein, Fc Tag
Human
HEK293
SDS-PAGE

$330.00

25ug
You Have Viewed 1-5 Of 5 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
CD37+CD22 CAR-TCell therapyOncology/CancerAMLPCCGlobal
Project Name
CD37+CD22 CAR-T
Drug Type
Cell therapy
Therapeutic Area
Oncology/Cancer
Indication
AML
Stage
PCC
Rights Area
Global
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Lutetium (177lu) lilotomab satetraxetan177Lu-DOTA-HH1Phase 2 ClinicalNordic Nanovector
Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin
Details
DS-3790aDS3790a; DS-3790aPhase 2 ClinicalDaiichi Sankyo Co Ltd
Hematologic Neoplasms
Details
Naratuximab emtansineIMGN-529; K7153A-SMCC-DM1Phase 2 ClinicalImmunogen Inc
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin
Details
Debio-1562MDebio-1562MPhase 2 ClinicalDebiopharm International Sa
Leukemia, Myeloid, Acute; Neoplasms
Details
AGS-67EAGS-67EPhase 1 ClinicalAgensys Inc
Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin
Details
CAR-37 T cell therapy (Massachusetts General Hospital)Phase 1 ClinicalMassachusetts General Hospital
Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Details
CAR-37 T cells(The General Hospital)Phase 1 ClinicalThe General Hospital Corporation D/B/A Massachusetts General Hospital
Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Details
anti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And Technology
Lymphoma, Non-Hodgkin
Details
DS3790DS-3790; DS3790ClinicalDaiichi Sankyo Inc
Hematologic Neoplasms
Details
Customer Reviews